Emmaus Life Sciences Inc.: Alex Denner’s Sarissa Capital Management filed an amended 13D.
You can check out Sarissa Capital Management’s latest holdings and filings here.
Please follow Sarissa Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Sarissa Capital Management or update its stock holdings.
Follow Alex Denner's Sarissa Capital Management
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Sarissa Capital Management | 8 | 497,657 | 10 | 497,657 | 497,657 | 1.4% |
Alexander J. Denner, Ph.D | 8 | 497,657 | 10 | 497,657 | 497,657 | 1.4% |
Sarissa Capital Offshore Master Fund | 497,657 | 9 | 497,657 | 11 | 497,657 | 1.4% |
Follow Alex Denner's Sarissa Capital Management
Page 1 of 6 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Emmaus Life Sciences, Inc. |
(Name of Issuer) |
Common Stock, $0.001 par value |
(Title of Class of Securities) |
29137P109 |
(CUSIP Number) |
Mark DiPaolo General Counsel Sarissa Capital Management LP 660 Steamboat Road Greenwich, CT 06830 203-302-2330 With a copy to: Russell Leaf Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, New York 10019 212-728-8000 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
March 29, 2018 |
(Date of Event which Requires Filing of this Statement) |
Follow Emmaus Life Sciences Inc.
Follow Emmaus Life Sciences Inc.
Page 2 of 6 – SEC Filing
CUSIP No. 29137P109 | Page 2 of 6 Pages |
1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sarissa Capital Management LP | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER | ||
8 | SHARED VOTING POWER 497,657 | |||
9 | SOLE DISPOSITIVE POWER | |||
10 | SHARED DISPOSITIVE POWER 497,657 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 497,657 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES: | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.4% | |||
14 | TYPE OF REPORTING PERSON PN |
Follow Emmaus Life Sciences Inc.
Follow Emmaus Life Sciences Inc.
Page 3 of 6 – SEC Filing
CUSIP No. 29137P109 | Page 3 of 6 Pages |
1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Alexander J. Denner, Ph.D. | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER | ||
8 | SHARED VOTING POWER 497,657 | |||
9 | SOLE DISPOSITIVE POWER | |||
10 | SHARED DISPOSITIVE POWER 497,657 | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 497,657 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES: | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.4% | |||
14 | TYPE OF REPORTING PERSON IN |
Follow Emmaus Life Sciences Inc.
Follow Emmaus Life Sciences Inc.
Page 4 of 6 – SEC Filing
CUSIP No. 29137P109 | Page 4 of 6 Pages |
1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Sarissa Capital Offshore Master Fund LP | |||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ | ||
3 | SEC USE ONLY | |||
4 | SOURCE OF FUNDS | |||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | ☐ | ||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands | |||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 497,657 | ||
8 | SHARED VOTING POWER | |||
9 | SOLE DISPOSITIVE POWER 497,657 | |||
10 | SHARED DISPOSITIVE POWER | |||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 497,657 | |||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES: | ☐ | ||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.4% | |||
14 | TYPE OF REPORTING PERSON PN |
Follow Emmaus Life Sciences Inc.
Follow Emmaus Life Sciences Inc.
Page 5 of 6 – SEC Filing
Follow Emmaus Life Sciences Inc.
Follow Emmaus Life Sciences Inc.
Page 6 of 6 – SEC Filing
By: | /s/Mark DiPaolo |
Name: Mark DiPaolo | |
Title: General Counsel |
By: | /s/Mark DiPaolo |
Name: Mark DiPaolo | |
Title: Authorized Person |
Alexander J. Denner